SEC 13F Intelligence

Managers / Q2 2023 · view latest →

BML Capital Management, LLC

CIK 0001616824 · 65 E CEDAR - SUITE 2, ZIONSVILLE, IN, 46077 · 317-344-2447

Reported Value
$111M
Q2 2023
Positions
31
Filings on Record
16
2019–present window
Filed
Jul 24, 2023
original filing

Summary

Bml Capital Management, LLC reported $111M in U.S.-listed holdings across 31 positions for Q2 2023.

Its largest position, Spdr, represents 16.5% of the portfolio.

Compared with Q1 2023, the fund opened 7 new positions and exited 7.

Portfolio Metrics

Turnover
+26.9%
vs prior filed quarter
Top-10 Concentration
+79.9%
share of reported value
Largest Position
+16.5%
Spdr
New / Exited
7 / 7
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’22: $105MQ4 ’22Q1 ’23: $116MQ2 ’23: $111MQ2 ’23Q3 ’23: $109MQ4 ’23: $132MQ4 ’23Q1 ’24: $152MQ2 ’24: $140MQ2 ’24Q3 ’24: $170MQ4 ’24: $161MQ4 ’24Q1 ’25: $124MQ2 ’25: $132MQ2 ’25Q3 ’25: $109MQ4 ’25: $116MQ4 ’25Q1 ’26: $156Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 37.5%ETP: 32.8%Other: 29.7%
  • Common Stock · 37.5% · $42M
  • ETP · 32.8% · $36M
  • Other · 29.7% · $33M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
AVIRATEA PHARMACEUTICALS INCNEW+2.24M2.24M+$8M$8M
QUINCE THERAPEUTICS INCNEW+1.41M1.41M+$2M$2M
CALCCALCIMEDICA INCNEW+88.8K88.8K+$356,012$356,012
AVROBIO INCNEW+256.3K256.3K+$243,489$243,489
LITSMEI PHARMA INCNEW+23.0K23.0K+$151,116$151,116
IVVDINVIVYD INCNEW+134.7K134.7K+$141,431$141,431
RAIN ONCOLOGY INCNEW+72.9K72.9K+$87,511$87,511
PASSAGE BIO INCADDED+1.72M2.06M+$2M$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2023

31 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1SPDR SER TRBLOOMBERG 1-3 MO16.52%$18M200.0K
2ISHARES TR0-3 MNTH TREASRY16.29%$18M180.0K
3CYTEIR THERAPEUTICS INCCOM7.60%$8M3.25M
4AVIRATEA PHARMACEUTICALS INChistory →COM7.52%$8M2.24M
5ADVMCHFADVERUM BIOTECHNOLOGIES INChistory →COM7.38%$8M5.16M
6PARDES BIOSCIENCES INCCOM6.17%$7M3.79M
7TALARIS THERAPEUTICS INCCOM5.47%$6M2.00M
8ATHIRA PHARMA INCCOM4.95%$6M1.86M
9CLYMELIEM THERAPEUTICS INChistory →COM3.99%$4M1.58M
10ANFABERCROMBIE & FITCH COhistory →CL A3.98%$4M117.5K
11ASTCASTROTECH CORPhistory →COM2.81%$3M220.4K
12ORMPORAMED PHARMACEUTICALS INChistory →COM NEW2.74%$3M850.0K
13QUINCE THERAPEUTICS INCCOM1.91%$2M1.41M
14PASSAGE BIO INCCOM1.74%$2M2.06M
15TOCAEURFORTE BIOSCIENCES INChistory →COM1.62%$2M1.74M
16ELVNENLIVEN THERAPEUTICS INChistory →COM1.36%$2M74.2K
17ABIOEURARCA BIOPHARMA INChistory →COM1.29%$1M706.9K
18TILLYS INCCL A1.20%$1M190.5K
19LSTALISATA THERAPEUTICS INCCOM0.81%$902,204243.8K
20VERRICA PHARMACEUTICALS INCCOM0.78%$865,500150.0K
21SURROZEN INCCOM0.72%$802,4961.46M
22MISTMILESTONE PHARMACEUTICALS INCOM0.70%$776,625272.5K
23RVPRETRACTABLE TECHNOLOGIES INCCOM0.69%$768,861668.6K
24NXTCEURNEXTCURE INCCOM0.50%$551,637306.5K
25GRPHGRAPHITE BIO INCCOM0.36%$395,957152.3K
26CALCCALCIMEDICA INCCOM NEW0.32%$356,01288.8K
27AVROBIO INCCOM0.22%$243,489256.3K
28LITSMEI PHARMA INCCOM0.14%$151,11623.0K
29IVVDINVIVYD INCCOM0.13%$141,431134.7K
30RAIN ONCOLOGY INCCOM0.08%$87,51172.9K
31NEOLEUKIN THERAPEUTICS INCCOM0.02%$19,71223.7K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$156M16May 6, 202613F-HRchanges · EDGAR ↗
Q4 2025$116M16Feb 3, 202613F-HRchanges · EDGAR ↗
Q3 2025$109M20Nov 10, 202513F-HRchanges · EDGAR ↗
Q2 2025$132M24Aug 11, 202513F-HRchanges · EDGAR ↗
Q1 2025$124M27May 7, 202513F-HRchanges · EDGAR ↗
Q4 2024$161M25Feb 7, 202513F-HRchanges · EDGAR ↗
Q3 2024$170M29Nov 5, 202413F-HRchanges · EDGAR ↗
Q2 2024$140M28Aug 7, 202413F-HRchanges · EDGAR ↗
Q1 2024$152M32Apr 24, 2024RESTATEMENTchanges · EDGAR ↗
Q4 2023$132M35Feb 2, 2024RESTATEMENTchanges · EDGAR ↗
Q3 2023$109M26Oct 23, 202313F-HRchanges · EDGAR ↗
Q2 2023$111M31Jul 24, 202313F-HRchanges · EDGAR ↗
Q1 2023$116M31Apr 14, 202313F-HRchanges · EDGAR ↗
Q4 2022$105M25Feb 13, 202313F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.